Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
O. Elneima (Leicester, United Kingdom), W. Ibrahim (Leicester, United Kingdom), C. Boddy (Leicester, United Kingdom), A. Murphy (Leicester, United Kingdom), P. Bradding (Leicester, United Kingdom), C. Brightling (Leicester, United Kingdom), S. Siddiqui (Leicester, United Kingdom). Characterisation of severe eosinophilic asthma patients who failed Mepolizumab therapy. 2227

Member's Comments

No comment yet.

Related content which might interest you: Mepolizumab efficacy in patients with severe eosinophilic asthma and bronchiectasis Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Evaluation of therapeutic response to anti-IL5 treatment in severe eosinophilic asthma patients no responders to omalizumab Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Mepolizumab in real-life treatment of severe eosinophilic asthma Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma Source: International Congress 2017 – Asthma management Year: 2017 Clinical response to mepolizumab in patients with severe eosinophilic asthma Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma Year: 2019 Experience with Mepolizumab in a cohort of patients with eosinophilic severe persistent asthma Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma Source: ERJ Open Res, 7 (4) 00465-2021; 10.1183/23120541.00465-2021 Year: 2021 Effects of omalizumab on markers of eosinophilic inflammation in patients with severe allergic asthma Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011 Real-life treatment of severe eosinophilic asthma with mepolizumab Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 The characteristics of treatment failure with omalizumab in patients with severe asthma: The impact of eosinophilic complication Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Rapid Benralizumab effectiveness in patients with severe eosinophilic asthma and bronchiectasis Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Endotypes of severe allergic asthma patients who clinically benefit from Anti-IgE therapy Source: International Congress 2018 – Studying novel biomarkers in asthma and COPD Year: 2018 Add-on omalizumab therapy for patients with severe persistent allergic (IgE-mediated) asthma: identifying which patients to treat and which patients respond Source: Eur Respir J 2006; 28: Suppl. 50, 440s Year: 2006 Real-life effectiveness of anti-IL-5(-receptor) antibody treatment in patients with severe eosinophilic asthma Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Evolution of patients with severe asthma treated with mepolizumab Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005 Asthma exacerbations and eosinophilic inflammation 6 months after treatment with mepolizumab in refractory eosinophilic asthma Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Prevalence of adrenal insufficiency in patients started on Mepolizumab for severe eosinophilic asthma. Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Mepolizumab improves activity limitation in severe eosinophilic asthma Source: International Congress 2017 – Notable abstracts in asthma Year: 2017 Differential treatment response to mepolizumab in severe eosinophilic asthma with nasal polyps Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020